Drug Profile
Research programme: anxiety and depression therapeutics - Affectis/Mitsubishi
Latest Information Update: 30 Jul 2007
Price :
$50
*
At a glance
- Originator Affectis Pharmaceuticals; Mitsubishi Pharma Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Mood disorders
Most Recent Events
- 30 Jul 2007 Discontinued - Preclinical for Affective disorders in Germany (unspecified route)
- 30 Jul 2007 Discontinued - Preclinical for Anxiety disorders in Germany (unspecified route)
- 07 Feb 2005 Preclinical trials in Affective disorders in Germany (unspecified route)